Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial).
Matsuoka N, Nakazawa D, Nishio S, Cho KY, Maoka T, Kaneshima N, Yamamoto R, Yamamoto J, Shimamoto M, Makita M, Iriuda S, Igarashi K, Ito Y, Kato A, Yoshikawa J, Kudo T, Nagashima T, Ito YM, Atsumi T. Matsuoka N, et al. Among authors: cho ky. BMJ Open. 2024 Nov 25;14(11):e084846. doi: 10.1136/bmjopen-2024-084846. BMJ Open. 2024. PMID: 39592158 Free PMC article.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Kameda R, Nomoto H, Cho KY, Kawata S, Omori K, Takeuchi J, Nagai S, Kurihara Y, Aoki S, Nakamura A, Atsumi T, Miyoshi H. Kameda R, et al. Among authors: cho ky. BMJ Open. 2020 Feb 6;10(2):e034883. doi: 10.1136/bmjopen-2019-034883. BMJ Open. 2020. PMID: 32034028 Free PMC article.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
Nomoto H, Furusawa S, Nakamura A, Takeuchi J, Nagai S, Yokoyama H, Sakuma I, Taneda S, Kurihara Y, Aoki S, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H. Nomoto H, et al. Among authors: cho ky. BMJ Open. 2022 May 18;12(5):e056885. doi: 10.1136/bmjopen-2021-056885. BMJ Open. 2022. PMID: 35584872 Free PMC article.
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H, Takahashi A, Nakamura A, Kurihara H, Takeuchi J, Nagai S, Taneda S, Miya A, Kameda H, Cho KY, Miyoshi H, Atsumi T. Nomoto H, et al. Among authors: cho ky. BMJ Open Diabetes Res Care. 2022 Nov;10(6):e002988. doi: 10.1136/bmjdrc-2022-002988. BMJ Open Diabetes Res Care. 2022. PMID: 36379585 Free PMC article.
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito YM, Atsumi T, Miyoshi H. Takahashi K, et al. Among authors: cho ky. J Diabetes Investig. 2019 Mar;10(2):429-438. doi: 10.1111/jdi.12913. Epub 2018 Sep 26. J Diabetes Investig. 2019. PMID: 30136403 Free PMC article.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H. Miya A, et al. Among authors: cho ky. J Diabetes Investig. 2021 Aug;12(8):1395-1399. doi: 10.1111/jdi.13479. Epub 2021 Jan 21. J Diabetes Investig. 2021. PMID: 33325645 Free PMC article. Clinical Trial.
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study.
Miya A, Nakamura A, Suzuki Y, Nomoto H, Kameda H, Cho KY, Ito YM, Nagai S, Miyoshi H, Atsumi T. Miya A, et al. Among authors: cho ky. Diabetes Obes Metab. 2023 Jul;25(7):1883-1889. doi: 10.1111/dom.15049. Epub 2023 Mar 31. Diabetes Obes Metab. 2023. PMID: 36906821
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Diabetes Obes Metab. 2020 Mar;22(3):458-462. doi: 10.1111/dom.13879. Epub 2019 Oct 13. Diabetes Obes Metab. 2020. PMID: 31486230 Free PMC article. Clinical Trial.
Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.
Miya A, Nakamura A, Miyoshi H, Cho KY, Nagai S, Kurihara Y, Aoki S, Taguri M, Terauchi Y, Atsumi T. Miya A, et al. Among authors: cho ky. J Diabetes Investig. 2018 Jan;9(1):119-126. doi: 10.1111/jdi.12654. Epub 2017 Jul 10. J Diabetes Investig. 2018. PMID: 28296201 Free PMC article. Clinical Trial.
238 results